Article
Biotechnology & Applied Microbiology
Long Zhang, Chaofeng Mu, Tinghong Zhang, Dejun Yang, Chenou Wang, Qiong Chen, Lin Tang, Luhui Fan, Cong Liu, Jianliang Shen, Huaqiong Li
Summary: By assembling RNase resistant RNA nanoparticles (NPs) based on the 3WJ structure from Phi29 DNA packaging motor, we successfully developed RNA NPs equipped with epidermal growth factor receptor (EGFR) targeting aptamer and XBP1 siRNA, which could deplete XBP1 expression, suppress tumor growth, sensitize TNBC to chemotherapy, and inhibit angiogenesis in vivo, demonstrating the potential of RNA NPs as an effective platform for siRNA delivery and therapy for chemotherapy-resistant TNBC.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Engineering, Biomedical
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Summary: Management of aggressive breast cancer, particularly TNBC, remains challenging despite advances in treatment. New therapies like atezolizumab, olaparib, and sacituzumab show limited survival benefits. Current research aims to improve treatment strategies by enhancing bioavailability, targetability, and reducing toxicity for better therapeutic outcomes.
BIOACTIVE MATERIALS
(2021)
Article
Oncology
Chia-Che Chang, Chien-Chih Chiu, Pei-Feng Liu, Chih-Hsuan Wu, Yen-Chiang Tseng, Cheng-Hsin Lee, Chih-Wen Shu
Summary: The study identified DYRK1B as a potential gene essential for cell proliferation and mobility of triple-negative breast cancer (TNBC) cells, particularly in those with high DYRK1B expression, which was associated with poor overall survival. CCDC97 and ZNF581 were positively correlated with DYRK1B expression. The results suggest DYRK1B as a potential therapeutic target for TNBC patients.
Review
Pharmacology & Pharmacy
Elda A. Flores-Contreras, Reyna Berenice Gonzalez-Gonzalez, Everardo Gonzalez-Gonzalez, Roberto Parra-Saldivar, Hafiz M. N. Iqbal
Summary: Breast cancer is a disease with different subtypes, including the aggressive triple-negative subtype. Traditional therapies may cause side effects, leading to the exploration of epigenetic regulators for potentially improved treatment of breast cancer. However, challenges like stability and targeting need to be addressed when using these regulators.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Kajal Rajput, Mohammad Nafees Ansari, Somesh K. Jha, Trishna Pani, Nihal Medatwal, Somdeb Chattopadhyay, Avinash Bajaj, Ujjaini Dasgupta
Summary: This study compares the sphingolipid profiles of triple-positive and triple-negative breast cancer patients and correlates them with cell proliferation and migration properties. Results show that targeting ceramide kinase (CERK) can slow down tumor progression, suggesting CERK as a potential therapeutic target for breast cancer.
Article
Materials Science, Biomaterials
Liang Chen, Mengsi Zhan, Jin Li, Liu Cao, Huxiao Sun, Regis Laurent, Serge Mignani, Anne-Marie Caminade, Jean-Pierre Majoral, Xiangyang Shi
Summary: This study introduces a nanosystem based on amphiphilic phosphorus dendron micelles for combination therapy of triple negative breast cancer. The micelles exhibit excellent stability and high drug loading efficiency. The co-delivery system of miR-21 inhibitor and doxorubicin can effectively inhibit cancer cells through different anticancer mechanisms, as demonstrated in in vivo experiments.
JOURNAL OF MATERIALS CHEMISTRY B
(2023)
Review
Oncology
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Summary: TNBC, characterized by absence of ER, PR, and HER2 expression, is a highly aggressive subtype of breast cancer. Conventional chemotherapy remains the main treatment, but the lack of targeted therapies has led to exploration of PARP inhibitors and immune checkpoint inhibitors as potential options. Other agents targeting various pathways are also under investigation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Manxiang Wu, Tianxiang Chen, Lianfu Wang, Ozioma Udochukwu Akakuru, Xuehua Ma, Jinshan Xu, Jiapeng Hu, Jia Chen, Qianlan Fang, Aiguo Wu, Qiang Li
Summary: This study developed a core membrane nanoplatform for enhanced treatment of triple-negative breast cancer (TNBC) using biomimetic nanotechnology and tumor microenvironment (TME) responsiveness. The nanoplatform showed precise drug delivery and improved oxygen levels in the tumor, resulting in enhanced chemotherapy/phototherapy. In addition, it exhibited good fluorescence and magnetic resonance imaging performances, enabling image-guided combination tumor therapy.
Article
Biochemistry & Molecular Biology
Wataru Sato, Kazuhiro Ikeda, Noriko Gotoh, Satoshi Inoue, Kuniko Horie
Summary: Efp plays a tumor-promotive role in TNBC and may serve as a potential therapeutic target for this aggressive disease.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Pharmacology & Pharmacy
Abdallah M. Ayoub, Ahmed M. Abdelsalam, Jan Schulze, Muhammad U. Amin, Konrad Engelhardt, Matthias Wojcik, Damiano Librizzi, Behrooz H. Yousefi, Usman Nasrullah, Josef Pfeilschifter, Udo Bakowsky, Eduard Preis
Summary: The application of photodynamic therapy in cancer treatment is crucial, but the lipophilic nature of most photosensitizers hinders their administration and causes aggregation in biological environments. Researchers encapsulated the natural photosensitizer parietin (PTN) in poly(lactic-co-glycolic acid) nanoparticles to overcome this limitation. The PTN nanoparticles displayed a size of 193.70 nm and 157.31 nm as characterized by dynamic light scattering and atomic force microscopy, respectively. The quantum yield and in vitro release of PTN nanoparticles were assessed, along with their effects on triple-negative breast cancer cells and angiogenic blood vessels. The results showed promising anticancer effects and a reduction in angiogenic blood vessels, suggesting that PTN nanoparticles could be an effective strategy for fighting cancer.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Pharmacology & Pharmacy
Rahul Chadar, Afsana, Prashant Kesharwani
Summary: Triple negative breast cancer is characterized by absence of estrogen receptor, progesterone receptor, and HER-2 receptor, leading to poor prognosis and chemoresistance. Advanced therapy using genes and nanocarrier can improve therapeutic outcomes with reduced side effects.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow, Suresh K. Alahari
Summary: Combination therapy with ceritinib and enzalutamide inhibits the growth of AR(+) TNBC cells, while combination therapy with ceritinib and paclitaxel drastically inhibits tumor growth. These findings suggest that combination treatment with these FDA-approved drugs can improve the therapeutic response in both AR-positive and negative breast cancer.
Article
Oncology
Na Xu, Baohong Li, Yong Liu, Cui Yang, Siqi Tang, William C. Cho, Zunnan Huang
Summary: This study identified biomarkers and potential targets for triple-negative breast cancer (TNBC) related to ferroptosis. A prognostic model composed of 12 ferroptosis-related genes was constructed and validated. Seven genes were identified as potential therapeutic targets, and two drugs were found to have potential for treating TNBC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Simona Camorani, Silvia Tortorella, Lisa Agnello, Chiara Spanu, Annachiara D'Argenio, Roberto Nilo, Antonella Zannetti, Erica Locatelli, Monica Fedele, Mauro Comes Franchini, Laura Cerchia
Summary: This study presents a novel aptamer-based platform for the targeted delivery of siRNA to triple-negative breast cancer cells. By utilizing cell-targeting and internalizing aptamers, this delivery system specifically delivers siRNA to TNBC cells, resulting in efficient suppression of PD-L1 expression.
Review
Oncology
Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov, Yongheng Chen
Summary: Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)